IVVD
Invivyd
Stock NASDAQ – Stock Market Prices, News & Analysis
Invivyd Inc, formerly known as Adagio Therapeutics, is a biotechnology company developing therapeutic solutions for the management of infectious diseases.
Invivyd
IVVD
Invivyd Inc, formerly known as Adagio Therapeutics, is a biotechnology company developing therapeutic solutions for the management of infectious diseases.
Price history of Invivyd
Price history of Invivyd
Performance & Momentum
Invivyd Reports Strong Q4 Growth, Launches COVID Antibody Phase 3
Invivyd announced preliminary product revenue of $17.2M for Q4 2025, up 25% year-over-year and 31% from the prior quarter, driven by its drug PEMGARDA. The company also initiated Phase 3 trials for VYD2311, an alternative COVID antibody to vaccines, with results expected by mid-2026. This trial benefits from Fast Track designation. Coupled with a strong $227M cash position, these clinical and financial strengths boost outlooks and have resulted in positive analyst consensus, targeting $10 per share.
Strategic Analysis
Invivyd • 2026
Invivyd Inc is positioned as a biotech company specializing in infectious diseases, with an approach focused on developing targeted therapeutic solutions rather than maintaining a broad portfolio. This specialization gives it a defensive and differentiated angle, but it remains typical of a development-stage company still dependent on clinical and regulatory success.
- Niche positioning in infectious diseases, a segment where medical innovation can create significant value if candidates clear clinical milestones
- High re-rating potential in the event of positive regulatory news or clinical validation
- Recent history of strong stock market visibility, indicating speculative interest or expectations around the pipeline
- High binary risk, inherent to a development-stage biotech with no mature industrial visibility
- Strong dependence on clinical progress, regulation, and financing
- Very deteriorated long-term performance profile, reflecting value creation that is still fragile
Momentum appears moderately positive, with recent underlying strength that remains unstable. The stock shows a marked rebound capability over an intermediate horizon, while still subject to periods of volatility and incomplete recovery, making it more of a tactical than a long-term holding at this stage.
Similar stocks to Invivyd
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
